Syngenis: Australia's Oligonucleotide Revolution

0:00Ever heard of oligo, nucleotides, or oligos for short? These tiny genetic tools are game changers in medicine, power in COVID tests, PCR kits, and precision drugs that target diseases at their DNA routes. Right now in Perth, Singenis Laptores is the only spot in Australia commercially cranking them out, with a lab in Bentley Technology Park that's already serving customers. Starting from old school drugs that blast biology broadly, oligos let us rewrite genetic code precisely silencing bad genes, editing genomes with, CRISPR, or spotting diseases early. Australia loses about $160 million in oligo work overseas yearly, but government R&D tax rebates up to 43.5% favor local jobs pushing that cash back home. Researchers love it, tighter IP control, faster turnaround, and no compliance headaches. Singenis draws top talent like founder professor Rakesh Vedu, RNA expert from Murdoch University,

1:04plus legends like Marvin Careathers, who invented. Modern DNA synthesis and advisor suit here Agrawal with over 400 patents. They're built on three pillars, manufacturing for revenue with 40 Aussie and Kiwi clients, AI-driven discovery, targeting Alzheimer's and Parkinson's, signatures, and diagnostics for quick tests on prostate cancer or infections, backed by heavy hitters like the parent institute, they're eyeing an ASX listing soon. With global markets hitting $15 billion by 2030, Singenis isn't just a quiet lab anymore, it's gearing up to anchor Australia's. Biotech future, blending local muscle with world-class precision. That's the story for today, Sydney News Today, driven by AI. I'm Corey with the story.